Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia
New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
Dendritic cell vaccine for the effective immunotherapy of breast cancer
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma
Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro
[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
Immunotherapy in Malignant Pleural Mesothelioma
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
Feasibility of modulated electro-hyperthermia in preoperative treatment for locally advanced rectal cancer: Early phase 2 clinical results
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives